Core One Labs Inc., a biotechnology research and development company, has revealed promising results from its animal studies targeting Alzheimer’s and Parkinson’s diseases. The studies were conducted by Core One’s subsidiary, Akome Biotechnologies Inc., in collaboration with research partners at the Universitat de Barcelona in Spain.
The studies focused on five bioactive compounds, known as Bio-Compounds A-E, which were selected for their potential to mitigate disrupted physiological processes associated with neurological and mental health disorders. These disorders include Alzheimer’s disease, Parkinson’s disease, ischemic stroke, and depression.
In the initial round of animal model studies, Bio-Compound A showed significant promise in reducing motor dysfunction, which is a key symptom of Parkinson’s disease and late-stage Alzheimer’s disease. Building on those results, Core One’s investigators received positive results for the remaining four bio-compounds in the second round of studies.
During the second round, animals were exposed to various concentrations of the respective bio-compounds, and their motility was closely evaluated. The data from these studies demonstrated a significant improvement in the animal models’ motility compared to the control group. Furthermore, as the dose concentration of the bio-compounds increased, the improvement in motility also increased, highlighting their potential therapeutic value.
Core One CEO Joel Shacker expressed excitement about the positive results and the potential for developing multiple treatments targeting global health issues. The diversified drug pipeline created through the testing of the five bio-compounds could significantly increase the company’s future revenue.
These recent animal studies, combined with the previous round of studies, underscore the enormous promise of all five bio-compounds currently under investigation. Core One remains dedicated to drug development and pre-clinical testing, with a particular focus on treating motor dysfunction related to neurological disorders such as Parkinson’s and Alzheimer’s.
Core One Labs Inc. is actively involved in the research and development of psychedelic medicines. The company is focused on bringing these compounds to market, developing novel delivery systems, and advancing psychedelic-assisted treatments. With its multi-faceted business approach, Core One aims to establish itself as a leader in the emerging psychedelics market.
It’s important to note that psilocybin, one of the substances being investigated by Core One, is currently classified as a Schedule III drug under Canadian law. The company emphasizes that it does not promote the recreational use or illegal distribution of psychedelic substances. Core One believes in the medically beneficial applications of these substances within approved regulatory frameworks and clinical trial settings.
With these promising animal study results, Core One Labs Inc. is poised to continue its research and development efforts in the field of neurological disorders. By targeting bio-compounds that show significant potential in treating motor dysfunction, the company aims to make a positive impact on the lives of those living with conditions like Parkinson’s and Alzheimer’s disease.
